Peter S. Hamblin

1.4k total citations
54 papers, 755 citations indexed

About

Peter S. Hamblin is a scholar working on Endocrinology, Diabetes and Metabolism, Epidemiology and Molecular Biology. According to data from OpenAlex, Peter S. Hamblin has authored 54 papers receiving a total of 755 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Endocrinology, Diabetes and Metabolism, 12 papers in Epidemiology and 11 papers in Molecular Biology. Recurrent topics in Peter S. Hamblin's work include Diabetes and associated disorders (8 papers), Thyroid Disorders and Treatments (8 papers) and Chronic Disease Management Strategies (6 papers). Peter S. Hamblin is often cited by papers focused on Diabetes and associated disorders (8 papers), Thyroid Disorders and Treatments (8 papers) and Chronic Disease Management Strategies (6 papers). Peter S. Hamblin collaborates with scholars based in Australia, United States and Denmark. Peter S. Hamblin's co-authors include Duncan J. Topliss, Jan R. Stockigt, Chen‐Fee Lim, David V. Tuxen, Douglas Lording, Elif I. Ekinci, John Barlow, Lawrence P. McMahon, Jeffrey D. Zajac and Mathis Grossmann and has published in prestigious journals such as Journal of Biological Chemistry, The Journal of Clinical Endocrinology & Metabolism and Diabetes Care.

In The Last Decade

Peter S. Hamblin

50 papers receiving 720 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter S. Hamblin Australia 16 451 139 135 109 103 54 755
Daniel Lorber United States 14 411 0.9× 99 0.7× 128 0.9× 161 1.5× 124 1.2× 24 792
Stephen Fava Malta 20 330 0.7× 109 0.8× 147 1.1× 156 1.4× 64 0.6× 78 1.0k
Sadanori Okada Japan 19 303 0.7× 56 0.4× 120 0.9× 144 1.3× 63 0.6× 50 887
Sing-Yu Yang Taiwan 15 383 0.8× 59 0.4× 103 0.8× 74 0.7× 46 0.4× 19 738
Ridha Arem United States 18 717 1.6× 114 0.8× 146 1.1× 156 1.4× 81 0.8× 37 998
Valeria Frighi United Kingdom 11 230 0.5× 87 0.6× 109 0.8× 124 1.1× 37 0.4× 16 584
Neil Poulter United Kingdom 9 342 0.8× 40 0.3× 94 0.7× 111 1.0× 86 0.8× 21 750
Yamini S. Levitzky United States 8 303 0.7× 52 0.4× 98 0.7× 132 1.2× 109 1.1× 11 968
P. Hougaard Denmark 6 348 0.8× 154 1.1× 90 0.7× 193 1.8× 40 0.4× 10 818

Countries citing papers authored by Peter S. Hamblin

Since Specialization
Citations

This map shows the geographic impact of Peter S. Hamblin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter S. Hamblin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter S. Hamblin more than expected).

Fields of papers citing papers by Peter S. Hamblin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter S. Hamblin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter S. Hamblin. The network helps show where Peter S. Hamblin may publish in the future.

Co-authorship network of co-authors of Peter S. Hamblin

This figure shows the co-authorship network connecting the top 25 collaborators of Peter S. Hamblin. A scholar is included among the top collaborators of Peter S. Hamblin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter S. Hamblin. Peter S. Hamblin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hamblin, Peter S., Anthony Russell, Stella Talic, & Sophia Zoungas. (2025). The growing range of complications of diabetes mellitus. Trends in Endocrinology and Metabolism. 36(10). 943–954. 10 indexed citations
2.
Omonaiye, Olumuyiwa, Elizabeth Holmes‐Truscott, Bodil Steen Rasmussen, et al.. (2025). Individual, Social and Environmental Factors Influencing Medication-Taking Among Adults of Vietnamese Heritage With Type 2 Diabetes Living in Australia: A Qualitative Study. Clinical Therapeutics. 47(5). e1–e11. 1 indexed citations
3.
4.
Deitch, Jessica, I‐Lynn Lee, Christopher J. Yates, et al.. (2024). Simplified gestational diabetes screening with a triaging fasting plasma glucose reduces the burden of oral glucose tolerance tests during pregnancy – A large tertiary comparative cohort study. Diabetes Research and Clinical Practice. 209. 111120–111120. 1 indexed citations
5.
Hamblin, Peter S., Arul Earnest, Anthony Russell, et al.. (2024). Utilization and cost of non‐insulin glucose‐lowering drugs in Australia from 2013 to 2023. Diabetes Obesity and Metabolism. 26(11). 4924–4932. 4 indexed citations
6.
Hamblin, Peter S., Arul Earnest, Anthony Russell, et al.. (2024). The impact of sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists on insulin utilisation and costs in Australia: a national retrospective observational cross-sectional study. The Lancet Regional Health - Western Pacific. 52. 101207–101207. 1 indexed citations
7.
Boehm, Emma, et al.. (2023). Systemic and iatrogenic factors contribute to the development of severe hypernatraemia in vulnerable inpatients. Clinical Endocrinology. 100(4). 350–357.
8.
Hagger, Virginia, et al.. (2022). The experiences and support needs of students with diabetes at university: An integrative literature review. Diabetic Medicine. 40(1). e14943–e14943. 5 indexed citations
9.
Opie, Rachelle, David Crawford, Stella O’Connell, et al.. (2022). Participants’ and Health Care Providers’ Insights Regarding a Web-Based and Mobile-Delivered Healthy Eating Program for Disadvantaged People With Type 2 Diabetes: Descriptive Qualitative Study. JMIR Formative Research. 7. e37429–e37429. 2 indexed citations
10.
Hamblin, Peter S., et al.. (2021). Diabetic ketoacidosis: a canary in the mine for mental health disorders?. Internal Medicine Journal. 52(6). 1002–1008. 5 indexed citations
11.
Hamblin, Peter S., Rosemary Wong, Elif I. Ekinci, et al.. (2021). Body mass index is inversely associated with capillary ketones at the time of colonoscopy: Implications for SGLT2i use. Clinical Endocrinology. 96(4). 549–557. 2 indexed citations
12.
Hamblin, Peter S., Bu B. Yeap, & David J. Torpy. (2021). Sepsis and adrenal insufficiency: a potentially lethal combination. The Medical Journal of Australia. 214(7). 334–334.
13.
Crawford, David, Rachelle Opie, Ralph Maddison, et al.. (2020). EatSmart, a Web-Based and Mobile Healthy Eating Intervention for Disadvantaged People With Type 2 Diabetes: Protocol for a Pilot Mixed Methods Intervention Study. JMIR Research Protocols. 9(11). e19488–e19488. 3 indexed citations
14.
Wong, Joshua, Elyssia Bourke, Seok Lim, et al.. (2020). Lead poisoning associated with illicit opium use. Internal Medicine Journal. 50(2). 239–242. 5 indexed citations
15.
Hamblin, Peter S., Rosemary Wong, & Leon A. Bach. (2020). Sodium–glucose cotransporter type 2 inhibitors: managing the small but critical risk of diabetic ketoacidosis. The Medical Journal of Australia. 212(7). 294–294. 1 indexed citations
16.
Hamblin, Peter S., et al.. (2020). Evolving Evidence of Diabetic Ketoacidosis in Patients Taking Sodium-Glucose Cotransporter 2 Inhibitors. The Journal of Clinical Endocrinology & Metabolism. 105(8). 2475–2486. 24 indexed citations
17.
18.
Hamblin, Peter S., Penelope M. Sheehan, Carolyn A Allan, et al.. (2018). Subclinical hypothyroidism during pregnancy: the Melbourne public hospitals consensus. Internal Medicine Journal. 49(8). 994–1000. 6 indexed citations
19.
Khong, Jwu Jin, Kathryn P. Burdon, Yi Lu, et al.. (2016). Pooled genome wide association detects association upstream of FCRL3 with Graves’ disease. BMC Genomics. 17(1). 939–939. 10 indexed citations
20.
Newnham, Harvey, et al.. (1987). EFFECT OF ORAL FRUSEMIDE ON DIAGNOSTIC INDICES OF THYROID FUNCTION. Clinical Endocrinology. 26(4). 423–431. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniel Lorber Breakdown of academic impact, for papers by Stephen Fava Breakdown of academic impact, for papers by Sadanori Okada Breakdown of academic impact, for papers by Sing-Yu Yang Breakdown of academic impact, for papers by Ridha Arem Breakdown of academic impact, for papers by Valeria Frighi Breakdown of academic impact, for papers by Neil Poulter Breakdown of academic impact, for papers by Yamini S. Levitzky Breakdown of academic impact, for papers by P. Hougaard
Rankless by CCL
2026